All In Biotech

Drug Trial Radar · NCT05506943

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

168

Actual

Start

Jan 9, 2023

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Compass TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.

Conditions

  • Biliary Tract Cancer
  • Cholangiocarcinoma
  • Gall Bladder Cancer
  • Ampullary Cancer

Interventions

  • CTX-009Drug

    IV infusion on day 1 and 14 of every 28 day cycle

  • PaclitaxelDrug

    IV infusion on day 1, 8, and 15 of every 28 day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Overall ResponseTime frame: From randomization to treatment discontinuation for any reason, average 6 months

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • University of Arizona

    Tucson, Arizona

  • University of Southern California Norris Comprehensive Cancer Center

    Los Angeles, California

  • Stanford Medicine Cancer Center

    Palo Alto, California

  • University of California San Francisco

    San Francisco, California

  • Rocky Mountain Cancer Centers, LLP

    Aurora, Colorado

  • University of Florida

    Gainesville, Florida

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Northwestern University

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Washington University School of Medicine, Siteman Cancer Center

    St Louis, Missouri

  • Rutgers Cancer Institute

    New Brunswick, New Jersey

  • The University of New Mexico

    Albuquerque, New Mexico

  • Memorial Medical Center

    Las Cruces, New Mexico

  • Roswell Park

    Buffalo, New York

  • Columbia University

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Gabrail Cancer Center

    Canton, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Texas Oncology - Austin

    Austin, Texas

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • Texas Oncology - Dension

    Denison, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology - San Antonio

    San Antonio, Texas

  • Texas Oncology - Northeast Texas

    Tyler, Texas

  • Virginia Mason Franciscan Health

    Seattle, Washington

  • Northwest Cancer Specialists, P.C.

    Vancouver, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.